Bausch Health Companies (NYSE:BHC) Price Target Cut to $8.50 by Analysts at Royal Bank of Canada

Bausch Health Companies (NYSE:BHC) had its price target trimmed by Royal Bank of Canada from $9.00 to $8.50 in a research note released on Monday morning,BayStreet.CA reports. The firm currently has a sector perform rating on the stock.

Separately, Jefferies Financial Group reiterated a “hold” rating and issued a $8.00 target price (down previously from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $7.17.

Bausch Health Companies Stock Performance

NYSE BHC opened at $5.26 on Monday. The stock has a 50-day simple moving average of $6.86 and a 200 day simple moving average of $7.67. Bausch Health Companies has a twelve month low of $3.96 and a twelve month high of $10.46. The stock has a market capitalization of $1.93 billion, a PE ratio of -43.79, a P/E/G ratio of 0.37 and a beta of 0.43.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.44). Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. The business had revenue of $2.56 billion for the quarter, compared to analyst estimates of $2.51 billion. As a group, equities research analysts forecast that Bausch Health Companies will post 4.41 EPS for the current fiscal year.

Hedge Funds Weigh In On Bausch Health Companies

Hedge funds and other institutional investors have recently made changes to their positions in the business. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Bausch Health Companies in the fourth quarter valued at about $468,000. Jefferies Financial Group Inc. grew its stake in shares of Bausch Health Companies by 12.5% in the 4th quarter. Jefferies Financial Group Inc. now owns 450,000 shares of the company’s stock valued at $3,627,000 after purchasing an additional 50,000 shares during the period. Mackenzie Financial Corp grew its stake in shares of Bausch Health Companies by 3.3% in the 4th quarter. Mackenzie Financial Corp now owns 208,106 shares of the company’s stock valued at $1,680,000 after purchasing an additional 6,591 shares during the period. Public Employees Retirement System of Ohio acquired a new position in shares of Bausch Health Companies in the 4th quarter worth approximately $927,000. Finally, Alpine Global Management LLC bought a new position in shares of Bausch Health Companies during the 4th quarter worth approximately $114,000. 78.65% of the stock is owned by institutional investors.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.